News

THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical trial recruitment is on track, and additional international clinical sites are set to open for OCTOPOD-IV US trial (OCTOPOD-IP) utilising intraperitoneal delivery has been initiated   Oxford UK, October 13, 2025.   Theolytics, a clinical-stage biotechnology company developing next-gene

Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer Oxford UK, October 7, 2025.   Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced the appointment of Matilde Saggese, MD, as Chief Medical Officer (CMO). Dr Saggese will lead clinical development and regulat

David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics. Dr Apelian joins as the company advances its first clinical trial with lead candidate THEO-260 in ovarian cancer. Oxford UK, December 17, 2024.  Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced the appointment of biotechnology industry leader David Apelian M